RT Journal Article
SR Electronic
T1 Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.25.20201459
DO 10.1101/2020.09.25.20201459
A1 Alcibiades Villarreal
A1 Giselle Rangel
A1 Xu Zhang
A1 Digna Wong
A1 Gabrielle Britton
A1 Patricia L. Fernandez
A1 Ambar Pérez
A1 Diana Oviedo
A1 Carlos Restrepo
A1 María B. Carreirra
A1 Dilcia Sambrano
A1 Gilberto Eskildsen
A1 Carolina De La Guardia
A1 Yamitzel Zaldivar
A1 Danilo Franco
A1 Sandra López-Vergès
A1 Dexi Zhang
A1 Fanjing Fan
A1 Baojun Wang
A1 Xavier Sáez-Llorens
A1 Rodrigo DeAntonio
A1 Ivonne Torres-Atencio
A1 Eduardo Ortega-Barria
A1 Rao Kosagisharaf
A1 Ricardo Lleonart
A1 Li Chong
A1 Amador Goodridge
A1 COVID-19 serology collaborator group
YR 2020
UL http://medrxiv.org/content/early/2020/09/25/2020.09.25.20201459.abstract
AB Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, which has reached 28 million cases worldwide in eight months. The serological detection of antibodies against the virus will play a pivotal role in complementing molecular tests to improve diagnostic accuracy, contact tracing, vaccine efficacy testing and seroprevalence surveillance. Here, we aimed first to evaluate a lateral flow assay’s ability to identify specific IgM and IgG antibodies against SARS-CoV-2 and second, to report the seroprevalence of these antibodies among health care workers and healthy volunteer blood donors in Panama. We recruited study participants between April 30th and July 7th, 2020. For the test validation and performance evaluation, we analyzed serum samples from participants with clinical symptoms and confirmed positive RT-PCR for SARS-CoV-2, participants with other confirmed infectious diseases, and a set of pre-pandemic serum samples. We used two by two table analysis to determine the test sensitivity and specificity as well as the kappa agreement value with a 95% confidence interval. Then, we used the lateral flow assay to determine seroprevalence among serum samples from COVID-19 patients, potentially exposed health care workers, and healthy volunteer donors. Our results show this assay reached a positive percent agreement of 97.2% (95% CI 84.2-100.0%) for detecting both IgM and IgG. The assay showed a kappa of 0.898 (95%CI 0.811-0.985) and 0.918 (95% CI 0.839-0.997) for IgM and IgG, respectively. The evaluation of serum samples from hospitalized COVID-19 patients indicates a correlation between test sensitivity and the number of days since symptom onset; the highest positive percent agreement (87% (95% CI 67.0-96.3%)) was observed at ≥15 days post-symptom onset. We found an overall antibody seroprevalence of 11.6% (95% CI 8.5-15.8%) among both health care workers and healthy blood donors. Our findings suggest this lateral flow assay could contribute significantly to implementing seroprevalence testing in locations with active community transmission of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Panama Secretaria Nacional de Ciencia Tecnologia e Innovacion (SENACYT) Rapid Grant No. COVID19-233 and Sistema Nacional de Investigacion (SNI). Additional support for personnel and field personnel was obtained from INDICASAT-AIP; a donation of commercial ELISA diagnosis kits was provided by the Club Rotario Panama Norte; the rapid test was donated by the Chinese Academy of Science; and the Key Research and Development Project of Hebei Province, China (20277705D) provided funding to Dr. Chong Li.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite Nacional de Bioetica de la Investigacion de Panama (CBNI) approval EC-CNBI-2020-03-43.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available upon request by email to agoodridge{at}indicasat.org.pa